BAAR, Switzerland, March 12, 2025--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the ...

BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its ...

(Oncotype DX乳がん再発スコア™ ) 結果が11から25の早期乳がんの女性における化学療法の効果判定に役立つ 来る主要医学会でのプレゼンテーションに提出される大規模前向きランダム化臨床試験の結果 カリフォルニア州レッドウッドシティ発、2018年3月15日 ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score ...

大腸癌の術後再発リスクを予測する遺伝子検査、Oncotype DX Colon Cancer Assayの有用性を示した大規模試験（CALGB 9581）の結果が、4月17日、Journal of Clinical Oncology（JCO）誌に発表された。 Oncotype DXは、再発に関連する複数の遺伝子の組み合わせにより癌の再発リスク ...

New data supports the value of the Oncotype DX Breast Recurrence Score® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally Exact ...

In the real world, as opposed to the controlled environment of clinical trials, use of the Oncotype DX (Genomic Health) test may not be as cost-effective as was thought. The gene expression profile ...

LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has ...